Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus
Conditions
Interventions
Following provision of informed consent, participants are randomised to one of two groups. At baseline, blood samples will be taken to assess levels of oxidative stress, inflammation and glycemic cont
Sponsors
National Autonomous University of Mexico
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 60 to 74 years old 2. Diagnosed with T2DM 3. No renal damage 4. Provision of informed consent
Exclusion criteria
Exclusion criteria: 1. People who have taken antioxidant supplements or anti-inflammatory drugs in the last 6 month 2. With hypothyroidism 3. Who presenting problems of digestive tract absorption or have been submitted to gastric surgery 4. With liver failure 5. Hypersensitivity to ALA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Oxidative stress is assessed by measuring the levels of SOD, GPx, TAS, TBARS and isoprostane markers measured in blood and plasma by spectrophotometry and ELISA, respectively, at baseline, 6 and 12 months 2. Inflammation is assessed by measuring serum levels of TNF-a, IL-1ß, IL-6, IL-8, IL-1, IL-12p70 by flow cytometry and PCR by turbidimetry at baseline, 6 and 12 months 3. Glycemic control is assessed by measuring HbA1c by turbidimetry and RAGE by ELISA, at baseline, 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum glucose levels and the lipid profile determined by spectrophometry, both performed in serum at the beginning of the study, 6 and 12 months 2. Blood pressure was measured using mercury sphygmomanometer, at baseline, 6 and 12 months | — |
Countries
Mexico
Outcome results
None listed